Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

被引：18

作者：

George, Daniel J. ^{[1
]}

Hessel, Colin ^{[2
]}

Halabi, Susan ^{[3
,4
]}

Michaelson, M. Dror ^{[5
]}

Hahn, Olwen ^{[6
]}

Walsh, Meghara ^{[7
]}

Picus, Joel ^{[8
]}

Small, Eric J. ^{[9
]}

Dakhil, Shaker ^{[10
]}

Feldman, Darren R. ^{[11
]}

Mangeshkar, Milan ^{[2
]}

Scheffold, Christian ^{[2
]}

Morris, Michael J. ^{[11
]}

Choueiri, Toni K. ^{[7
]}

机构：

[1] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA

[2] Exelixis Inc, Alameda, CA USA

[3] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA

[4] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[6] Alliance Protocol Operat Off, Chicago, IL USA

[7] Dana Farber Partners CancerCare, Boston, MA USA

[8] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[9] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Univ Kansas Wichita, Wichita, KS USA

[11] Memorial Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGIST | 2019年 / 24卷 / 11期

关键词：

THERAPY;

D O I：

10.1634/theoncologist.2019-0316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

引用

页码：1497 / 1501

页数：5

共 50 条

[41] Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma
Michaelson, D.
McDermott, D. F.
Atkins, M. B.
Cho, D. C.
Olivier, K. M.
Schwarzberg, A. B.
Choueiri, T. K.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[42] ADJUVANT SUNITINIB IN PATIENTS WITH HIGH RISK RENAL CELL CARCINOMA: SUBGROUP ANALYSES FROM S-TRAC TRIAL
Pantuck, Allan
Patard, Jean-Jacques
Patel, Anup
Ravaud, Alain
Motzer, Robert J.
Pandha, Hardev S.
George, Daniel J.
Chang, Yen-Hwa
Escudier, Bernard
Donskov, Frede
Magheli, Ahmed
Carteni, Giacomo
Laguerre, Brigitte
Tomczak, Piotr
Breza, Jan
Gerletti, Paola
Lechuga, Mariajose
Lin, Xun
Casey, Michelle
Staehler, Michael
JOURNAL OF UROLOGY, 2017, 197 (04): : E62 - E63
[43] Phase 2 Trial of Sunitinib and Gemcitabine in Patients With Sarcomatoid and/or Poor-Risk Metastatic Renal Cell Carcinoma
Michaelson, M. Dror
McKay, Rana R.
Werner, Lillian
Atkins, Michael B.
Van Allen, Eliezer M.
Olivier, Kara M.
Song, Jiaxi
Signoretti, Sabina
McDermott, David F.
Choueiri, Toni K.
CANCER, 2015, 121 (19) : 3435 - 3443
[44] Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Donskov, Frede
Motzer, Robert J.
Voog, Eric
Hovey, Elizabeth
Gruellich, Carsten
Nott, Louise M.
Cuff, Katharine
Gil, Thierry
Jensen, Niels Viggo
Chevreau, Christine
Negrier, Sylvie
Depenbusch, Reinhard
Bergmann, Lothar
Cornelio, Izzy
Champsaur, Anne
Escudier, Bernard
Pal, Sumanta
Powles, Thomas
Choueiri, Toni K.
EUROPEAN JOURNAL OF CANCER, 2020, 126 : 1 - 10
[45] Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC)
Grimm, Marc-Oliver
Mcdermott, David F.
Choueiri, Toni K.
Motzer, Robert J.
Frontera, Osvaldo Aren
George, Saby
Powles, Thomas
Donskov, Frede
Harrison, Michael R.
Rodriguez-Cid, Jeronimo
Ishii, Yuko
Mchenry, Brent
Rini, Brian I.
Tannir, Nizar M.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 70 - 71
[46] CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
McDermott, David F.
Choueiri, Toni K.
Motzer, Robert J.
Aren, Osvaldo Rudy
George, Saby
Powles, Thomas
Donskov, Frede
Harrison, Michael Roger
Cid, Jeronimo Rafael Rafael Rodriguez
Ishii, Yuko
McHenry, M. Brent
Mekan, Sabeen Fatima
Rini, Brian I.
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[47] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
Haanen, J. B. A. G.
Larkin, J.
Choueiri, T. K.
Albiges, L.
Rini, B. I.
Atkins, M. B.
Schmidinger, M.
Penkov, K.
Michelon, E.
Wang, J.
Mariani, M.
di Pietro, A.
Motzer, R. J.
ESMO OPEN, 2023, 8 (03)
[48] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE
Branchoux, S.
Negrier, S.
de Peretti, C.
Malcolm, B.
May, J.
Marie, L.
Gaudin, A. F.
Klijn, S.
Ignacio, T. J.
VALUE IN HEALTH, 2019, 22 : S477 - S477
[49] Comparison of sunitinib (su) versus temsirolimus (tern) in patients (pts) with poor risk metastatic renal cell carcinoma (prmRCC).
Neiman, Victoria
Keizman, Daniel
Sella, Avishay
Rosenbaum, Eli
Gottfried, Maya
Maimon, Natalie
Sarid, David
Gez, Eli
Carducci, Michael Anthony
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Peer, Avivit
Neumann, Avivit
Kovel, Svetlana
Mermershtain, Wilmosh
Rouvinov, Keren
Feldhamer, Ilan
Berger, Raanan
Hammerman, Ariel
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[50] A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.
McKay, Rana R.
Choueiri, Toni K.
Werner, Lillian
Atkins, Michael B.
Olivier, Kara M.
Song, Jiaxi
Signoretti, Sabina
McDermott, David F.
Michaelson, M. Dror
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)

← 1 2 3 4 5 →